Targeted immunomodulatory drugs (IMiDs) remain a core pillar in managing plasma cell malignancies and relapsed refractory conditions. Detailed analysis within the Immunomodulator For Multiple Myeloma Market report outlines how these therapies stimulate T-cell activity, promote natural killer cell response, and directly induce myeloma cell apoptosis. Clinical researchers leverage these targeted...